Redefining the approach to advanced prostate cancer

Industry session by JANSSEN PHARMACEUTICA NV

Location: Room Milan, North Hall (Level 1)

Chairs: K. Fizazi, Villejuif (FR)
        K. Miller, Berlin (DE)

Aims and objectives of this session
At the end of this symposium delegates should be able to:
• Explain the importance of different mHSPC presentations and tumour load, and how this may influence management
• Analyse the evidence for selecting a certain treatment from the current treatment options for mCRPC
• Explain the importance of comorbidities, drug interactions, and other patient characteristics, and how these can affect treatment decisions for patients with metastatic prostate cancer
• Describe the importance of investigating and developing biomarkers that might drive therapeutic decisions for patients with prostate cancer in the future

18:00 - 18:05
Welcome and introduction
K. Miller, Berlin (DE)

18:05 - 18:25
Should all patients get docetaxel for metastatic hormone-sensitive prostate cancer?
K. Fizazi, Villejuif (FR)

18:25 - 18:45
Should all patients get androgen-targeted therapy for first-line in metastatic castration-resistant prostate cancer?
K. Miller, Berlin (DE)

18:45 - 19:05
Panel discussion - Treating the patient with metastatic disease: Clinical case discussions
C.P. Evans, Sacramento (US)
K. Fizazi, Villejuif (FR)
K. Miller, Berlin (DE)

19:05 - 19:25
CRPC Variants and clinical implications
C.P. Evans, Sacramento (US)

19:25 - 19:30
Close of meeting
K. Fizazi, Villejuif (FR)